Biopsy Sciences to Market Core Cardiovascular Device in Europe

Published: Jan 31, 2013

Biopsy Sciences LLC received approval to market its new Magne-Cath medical device to the European market, starting this quarter. The Magne-Cath was developed to use in cardiovascular procedures to retrieve or manipulate objects during stent graft replacement, according to a written statement. The device makes stent graft procedures faster and improves safety. Clearwater-based Biopsy Sciences has requested but not yet received U.S. Food and Drug Administration approval to sell Magne-Cath in this country, but received the European approval to market it there, a company spokesman said.

Back to news